Sana M Al-Khatib1, Sean D Pokorney2, Hussein R Al-Khalidi3, Kevin Haynes4, Crystal Garcia5, David Martin6, Jennifer C Goldsack7, Thomas Harkins8, Noelle M Cocoros5, Nancy D Lin9, Hana Lipowicz5, Debbe McCall10, Vinit Nair8, Lauren Parlett4, Cheryl N McMahill-Walraven11, Richard Platt5, Christopher B Granger2. 1. Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. Electronic address: alkha001@mc.duke.edu. 2. Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. 3. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC. 4. HealthCore, Inc., Wilmington, DE. 5. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA. 6. US Food and Drug Administration, Silver Spring, MD. 7. The Clinical Trials Transformation Initiative, Durham, NC. 8. Humana Healthcare Research, Louisville, KY. 9. OptumInsight Life Sciences, Boston, MA. 10. Rowan Tree Perspectives Consulting, Murrieta, CA. 11. Aetna, Inc., Blue Bell, PA.
Abstract
BACKGROUND: Many studies showing underuse of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) predated the advent of the non-vitamin K antagonist OACs. We retrospectively examined use of OACs in a large commercially insured population. METHODS: Administrative claims data from 4 research partners participating in FDA-Catalyst, a program of the Sentinel Initiative, were queried in September 2017. Patients were included if they were ≥30 years old with ≥365 days of medical/pharmacy coverage, and had ≥2 diagnosis codes for AF, a CHA2DS2-VASc score ≥2, absence of contraindications to OAC use, and no evidence of OAC use in the 365 days before the index AF diagnosis. The main outcome measures of the current analysis were rates of OAC use in the prior 12 months of cohort identification and factors associated with non-use. RESULTS: A total of 197,806 AF patients met the eligibility criteria prior to assessment of OAC treatment. Of these, 179,580 (91%) patients were ≥65 years old and 73,286 (37%) patients were ≥80 years old. Half of the patients (98,903) were randomized to the early intervention arm in the IMPACT-AFib trial and constitute the cohort for this analysis. Of these, 32,295 (33%) had no evidence of OAC use in the prior 12 months. Compared with patients with evidence of OAC use in the prior 12 months, patients without OAC use were more likely to be ≥80 years old, women, and have a history of anemia (51% vs 47%) and less likely to have diabetes (41% vs 44%), history of stroke or TIA (15% vs 19%), and history of heart failure (39% vs 48%). CONCLUSIONS: Despite a high risk of stroke, one-third of privately insured patients with AF and no obvious contraindications to an OAC were not treated with an OAC. There is an unmet need for evidence-based interventions that could lead to greater use of OACs in patients with AF at risk for stroke.
RCT Entities:
BACKGROUND: Many studies showing underuse of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) predated the advent of the non-vitamin K antagonist OACs. We retrospectively examined use of OACs in a large commercially insured population. METHODS: Administrative claims data from 4 research partners participating in FDA-Catalyst, a program of the Sentinel Initiative, were queried in September 2017. Patients were included if they were ≥30 years old with ≥365 days of medical/pharmacy coverage, and had ≥2 diagnosis codes for AF, a CHA2DS2-VASc score ≥2, absence of contraindications to OAC use, and no evidence of OAC use in the 365 days before the index AF diagnosis. The main outcome measures of the current analysis were rates of OAC use in the prior 12 months of cohort identification and factors associated with non-use. RESULTS: A total of 197,806 AFpatients met the eligibility criteria prior to assessment of OAC treatment. Of these, 179,580 (91%) patients were ≥65 years old and 73,286 (37%) patients were ≥80 years old. Half of the patients (98,903) were randomized to the early intervention arm in the IMPACT-AFib trial and constitute the cohort for this analysis. Of these, 32,295 (33%) had no evidence of OAC use in the prior 12 months. Compared with patients with evidence of OAC use in the prior 12 months, patients without OAC use were more likely to be ≥80 years old, women, and have a history of anemia (51% vs 47%) and less likely to have diabetes (41% vs 44%), history of stroke or TIA (15% vs 19%), and history of heart failure (39% vs 48%). CONCLUSIONS: Despite a high risk of stroke, one-third of privately insured patients with AF and no obvious contraindications to an OAC were not treated with an OAC. There is an unmet need for evidence-based interventions that could lead to greater use of OACs in patients with AF at risk for stroke.
Authors: Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf Journal: N Engl J Med Date: 2011-08-10 Impact factor: 91.245
Authors: Emily C O'Brien; DaJuanicia N Simon; Larry A Allen; Daniel E Singer; Gregg C Fonarow; Peter R Kowey; Laine E Thomas; Michael D Ezekowitz; Kenneth W Mahaffey; Paul Chang; Jonathan P Piccini; Eric D Peterson Journal: Am Heart J Date: 2014-07-11 Impact factor: 4.749
Authors: Noelle M Cocoros; Sean D Pokorney; Kevin Haynes; Crystal Garcia; Hussein R Al-Khalidi; Sana M Al-Khatib; Patrick Archdeacon; Jennifer C Goldsack; Thomas Harkins; Nancy D Lin; David Martin; Debbe McCall; Vinit Nair; Lauren Parlett; Robert Temple; Cheryl McMahill-Walraven; Christopher B Granger; Richard Platt Journal: Clin Trials Date: 2018-11-16 Impact factor: 2.486
Authors: Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin Journal: N Engl J Med Date: 2011-08-27 Impact factor: 91.245
Authors: Stuart J Connolly; John Eikelboom; Campbell Joyner; Hans-Christoph Diener; Robert Hart; Sergey Golitsyn; Greg Flaker; Alvaro Avezum; Stefan H Hohnloser; Rafael Diaz; Mario Talajic; Jun Zhu; Prem Pais; Andrzej Budaj; Alexander Parkhomenko; Petr Jansky; Patrick Commerford; Ru San Tan; Kui-Hian Sim; Basil S Lewis; Walter Van Mieghem; Gregory Y H Lip; Jae Hyung Kim; Fernando Lanas-Zanetti; Antonio Gonzalez-Hermosillo; Antonio L Dans; Muhammad Munawar; Martin O'Donnell; John Lawrence; Gayle Lewis; Rizwan Afzal; Salim Yusuf Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245
Authors: Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray Journal: Circulation Date: 2013-12-17 Impact factor: 29.690
Authors: Ajay K Kakkar; Iris Mueller; Jean-Pierre Bassand; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Werner Hacke; Gregory Y H Lip; Lorenzo G Mantovani; Alexander G G Turpie; Martin van Eickels; Frank Misselwitz; Sophie Rushton-Smith; Gloria Kayani; Peter Wilkinson; Freek W A Verheugt Journal: PLoS One Date: 2013-05-21 Impact factor: 3.240
Authors: Sruthi Adimadhyam; Erin F Barreto; Noelle M Cocoros; Sengwee Toh; Jeffrey S Brown; Judith C Maro; Jacqueline Corrigan-Curay; Gerald J Dal Pan; Robert Ball; David Martin; Michael Nguyen; Richard Platt; Xiaojuan Li Journal: J Am Soc Nephrol Date: 2020-10-19 Impact factor: 10.121
Authors: Shirley V Wang; James R Rogers; Yinzhu Jin; David DeiCicchi; Sara Dejene; Jean M Connors; David W Bates; Robert J Glynn; Michael A Fischer Journal: BMJ Qual Saf Date: 2019-06-26 Impact factor: 7.035
Authors: Anders Johnson; Steven G Hershman; Ali Javed; C Mikael Mattsson; Jeffrey Christle; Marily Oppezzo; Euan A Ashley Journal: J Cardiovasc Transl Res Date: 2022-09-22 Impact factor: 3.216
Authors: Sean D Pokorney; Noelle Cocoros; Hussein R Al-Khalidi; Kevin Haynes; Shuang Li; Sana M Al-Khatib; Jacqueline Corrigan-Curay; Meighan Rogers Driscoll; Crystal Garcia; Sara B Calvert; Thomas Harkins; Robert Jin; Daniel Knecht; Mark Levenson; Nancy D Lin; David Martin; Debbe McCall; Cheryl McMahill-Walraven; Vinit Nair; Lauren Parlett; Andrew Petrone; Robert Temple; Rongmei Zhang; Yunping Zhou; Richard Platt; Christopher B Granger Journal: JAMA Netw Open Date: 2022-05-02
Authors: Muhammad Bilal Munir; Patrick Hlavacek; Allison Keshishian; Jennifer D Guo; Rajesh Mallampati; Mauricio Ferri; Cristina Russ; Birol Emir; Matthew Cato; Huseyin Yuce; Jonathan C Hsu Journal: PLoS One Date: 2022-02-17 Impact factor: 3.240